Scientific exchange · Dr. Javier Zimmermann

17 Jul 2026 · Virtual · Dr. Javier Zimmermann, Christie NHS Foundation Trust · MSL Dr. Anna Becker · Nephrada

ReviewedVeeva CRMENG-0158—

Capture insight from this engagement

Location: Christie NHS Foundation Trust
Therapeutic area: Nephrology
Country: United Kingdom
Stakeholder tier: Tier 2
Strategic objective: Not linked
Initiative: Not linked
MSL: ABDr. Anna BeckerMSL, Nephrology (DACH)
Product: Nephrada (nephradin)

Topics discussed

Patient-reported outcomes
APRIL pathway mechanism
Proteinuria as surrogate endpoint

Scientific content used

APRIL-IgAN Phase III topline

Questions raised

How does proteinuria reduction at 9 months translate to eGFR benefit?

Notes

Scientific exchange with community nephrologist at Christie NHS Foundation Trust. Discussed patient-reported outcomes, april pathway mechanism, proteinuria as surrogate endpoint.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

No follow-ups recorded.

Quality ratings

1–5, rated at review

Scientific relevance: 4
Strategic relevance: 5
Depth of exchange: 4
Actionability: 3

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0158

Audit history (0)

All create, update and approval events for this record

No audit events in sample data